about
Korean clinical practice guideline for benign prostatic hyperplasiaClinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an updateOveractive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introductionThe new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitorsLower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.Influence of sildenafil on blood oxygen saturation of the obstructed bladderCombination therapy for erectile dysfunction: an update review.The effect of transurethral resection of the prostate on erectile function in patients with benign prostatic hyperplasiaEffects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.Recent advances in management of bladder overactivity.Prospective pharmacologic therapies for the overactive bladderNovel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.Drugs and future candidates.Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?Alpha1-adrenoceptor subtypes and lower urinary tract symptomsCorrelation between risk factors for vascular disease and the American Urological Association Symptom Score.Lower urinary-tract symptoms and testosterone in elderly menA survey of commonalities relevant to function and dysfunction in pelvic and sexual organs.Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.The medical treatment of overactive bladder, including current and future treatments.Update on the sexual impact of treatment for benign prostatic hyperplasia.Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.The role of phosphodiesterases in bladder pathophysiology.The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.Non-Hormonal treatment of BPH/BOONeural control of lower urinary tract and targets for pharmacological therapy.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Chronic Administration of Tadalafil Improves the Symptoms of Patients with Amicrobic MAGI: An Open Study.
P2860
Q26766302-883B680C-78CF-43EB-8C08-0103DDBDA890Q26775925-C83555AC-83D2-4C64-9D78-6010D5D0CD03Q27011502-06F829BC-3935-4EF6-B81A-75F4EB732D52Q27025700-BBCD53A4-FBF4-44E0-9B57-4E5981A5B79AQ33289952-EF2B11D0-EF01-4453-9374-687219723FC2Q33706631-8E414AC6-3A0C-4D7F-99C7-E027DA4C675AQ33767906-4607D8A9-CDA4-47CD-A23D-A8E557723448Q33851191-DB53297A-4C16-4FBF-A853-B22E1AE658FDQ34075988-39772B12-3FF8-4BDF-BFE2-BC189C56A58FQ34114694-1322189D-0A50-48C9-8AB4-219EF628622EQ34167658-C91B88D3-D368-4503-A6CA-699DDDA8EF40Q35076367-9A2FB8E2-8C40-4D6F-AC66-576762862EC3Q35089850-97142570-7A1D-42CA-A74B-CFEE327E7ED8Q35183603-70AAB3CE-4718-49D3-9BB8-130C128EE405Q35347721-2A0B85D4-C221-4BFA-9E5D-14EED839349FQ35637347-BD069CB6-05CA-49DA-A656-3199FA5B7D80Q35993920-8AF90788-0DEE-4A67-9710-6FBAB5C1B284Q36206614-6FA85781-87F3-4BEB-A22C-9D3CE4EB85D2Q36360868-4D728AE8-B20C-4B76-A855-200AC4BB2E2DQ36371582-1490466A-371A-44E9-809B-B4586CF7FE75Q36409148-4B94E5DF-3B30-4BAE-8419-E61AB8F63508Q36579735-35B7A5BB-6AA0-4B0A-9008-3BEDD4A872ABQ36709646-2E26791E-38C7-41EF-81CD-9DE78B0C3765Q36839032-1D92C988-DE43-4DD2-82B8-DC3CFA802D16Q36918641-4806845B-4A26-4439-A4CB-6DB319AC88D9Q37018954-4F49C5C8-832D-47F4-9D38-E5ECCB2971D5Q37025381-48771AFB-72EB-420C-9EEE-1FBC271F0612Q37038183-08B00EE9-B899-4EE8-BAB2-6818AC75464CQ37624310-2829BA57-BD59-47D3-8F9C-8DB46CD3930EQ37719924-8F56D5DD-737D-48D6-B853-A9B1629ED63FQ37836943-36634EC2-257E-4578-BF72-0ED114658942Q38052091-579C5642-C197-4513-B12D-204288C5F04AQ38079523-6FF5C5C6-A234-4B9A-8361-560FA091F783Q38093143-DEB71C6D-5829-4D9F-BFC0-B21F77BF9F4BQ38106628-93E69E46-53D8-4FF9-A9FE-E37E0963DE4BQ38153654-843078BF-7214-40A5-9158-072C21FA2722Q38205423-1699CE51-3895-4C16-9F55-E382165C4E86Q38227058-F03D1816-9044-4620-A783-7EB19316E36DQ38815890-D3D9FB65-010A-409D-8F58-14507B077526Q41961516-802A3574-0736-4E1F-AFBC-F96BAB36196F
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Sildenafil influences lower urinary tract symptoms.
@ast
Sildenafil influences lower urinary tract symptoms.
@en
type
label
Sildenafil influences lower urinary tract symptoms.
@ast
Sildenafil influences lower urinary tract symptoms.
@en
prefLabel
Sildenafil influences lower urinary tract symptoms.
@ast
Sildenafil influences lower urinary tract symptoms.
@en
P2093
P1433
P1476
Sildenafil influences lower urinary tract symptoms
@en
P2093
D C Hanbury
E Kulinskaya
G B Boustead
P304
P356
10.1046/J.1464-410X.2002.03040.X
P577
2002-12-01T00:00:00Z